JP7664680B2 - ピロロベンゾジアゼピン二量体前駆体及びそのリガンド－リンカーコンジュゲート化合物 - Google Patents

ピロロベンゾジアゼピン二量体前駆体及びそのリガンド－リンカーコンジュゲート化合物 Download PDF

Info

Publication number
JP7664680B2
JP7664680B2 JP2019515212A JP2019515212A JP7664680B2 JP 7664680 B2 JP7664680 B2 JP 7664680B2 JP 2019515212 A JP2019515212 A JP 2019515212A JP 2019515212 A JP2019515212 A JP 2019515212A JP 7664680 B2 JP7664680 B2 JP 7664680B2
Authority
JP
Japan
Prior art keywords
substituted
compound
alkyl
unsubstituted
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019515212A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020512270A5 (enExample
JP2020512270A (ja
Inventor
ユン ソン，ホ
ミン キム，スン
レ キム，ヒョン
ウン パーク，キュン
チュン，チュル－ウン
パーク，ユン－へ
ジュン チョイ，ヒョ
イン リー，ス
ベク，ジュエル
ジュン リー，ヒュン
ユン リー，ジュ
オー，ジヘ
チェ，ジェイウク
スー オー，ヨン
ジュ キム，ヨン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ligachem Biosciences Inc
Original Assignee
Ligachem Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ligachem Biosciences Inc filed Critical Ligachem Biosciences Inc
Priority claimed from PCT/KR2018/003744 external-priority patent/WO2018182341A1/ko
Publication of JP2020512270A publication Critical patent/JP2020512270A/ja
Publication of JP2020512270A5 publication Critical patent/JP2020512270A5/ja
Priority to JP2023081396A priority Critical patent/JP2023113699A/ja
Application granted granted Critical
Publication of JP7664680B2 publication Critical patent/JP7664680B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/552—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being an antibiotic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
JP2019515212A 2017-03-29 2018-03-29 ピロロベンゾジアゼピン二量体前駆体及びそのリガンド－リンカーコンジュゲート化合物 Active JP7664680B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023081396A JP2023113699A (ja) 2017-03-29 2023-05-17 ピロロベンゾジアゼピン二量体前駆体及びそのリガンド－リンカーコンジュゲート化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR10-2017-0039841 2017-03-29
KR20170039841 2017-03-29
KR10-2018-0036895 2018-03-29
PCT/KR2018/003744 WO2018182341A1 (ko) 2017-03-29 2018-03-29 피롤로벤조디아제핀 이량체 전구체 및 이의 리간드-링커 접합체 화합물
KR1020180036895A KR101938800B1 (ko) 2017-03-29 2018-03-29 피롤로벤조디아제핀 이량체 전구체 및 이의 리간드-링커 접합체 화합물

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023081396A Division JP2023113699A (ja) 2017-03-29 2023-05-17 ピロロベンゾジアゼピン二量体前駆体及びそのリガンド－リンカーコンジュゲート化合物

Publications (3)

Publication Number Publication Date
JP2020512270A JP2020512270A (ja) 2020-04-23
JP2020512270A5 JP2020512270A5 (enExample) 2021-05-13
JP7664680B2 true JP7664680B2 (ja) 2025-04-18

Family

ID=63876096

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019515212A Active JP7664680B2 (ja) 2017-03-29 2018-03-29 ピロロベンゾジアゼピン二量体前駆体及びそのリガンド－リンカーコンジュゲート化合物
JP2023081396A Pending JP2023113699A (ja) 2017-03-29 2023-05-17 ピロロベンゾジアゼピン二量体前駆体及びそのリガンド－リンカーコンジュゲート化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023081396A Pending JP2023113699A (ja) 2017-03-29 2023-05-17 ピロロベンゾジアゼピン二量体前駆体及びそのリガンド－リンカーコンジュゲート化合物

Country Status (9)

Country Link
US (2) US11654197B2 (enExample)
EP (1) EP3604311A4 (enExample)
JP (2) JP7664680B2 (enExample)
KR (4) KR101938800B1 (enExample)
CN (1) CN109790171B (enExample)
AU (1) AU2018246806B2 (enExample)
CA (1) CA3058360A1 (enExample)
IL (1) IL269535B2 (enExample)
MX (1) MX2019011655A (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017089894A1 (en) 2015-11-25 2017-06-01 Legochem Biosciences, Inc. Conjugates comprising peptide groups and methods related thereto
CA3006249A1 (en) 2015-11-25 2017-06-01 Legochem Biosciences, Inc. Antibody-drug conjugates comprising branched linkers and methods related thereto
HRP20240795T1 (hr) 2015-11-25 2024-09-13 Ligachem Biosciences Inc. Konjugati koji se sastoje od samozapaljujućih skupina i postupci povezani s njima
IL269535B2 (en) 2017-03-29 2024-11-01 Ligachem Biosciences Inc Pyrrolobenzodiazepine dimer prodrug and ligand-linker conjugate compound of the same
GB201803342D0 (en) * 2018-03-01 2018-04-18 Medimmune Ltd Methods
EP3790591A4 (en) 2018-05-09 2022-05-11 LegoChem Biosciences, Inc. Compositions and methods related to anti-cd19 antibody drug conjugates
WO2020141923A2 (ko) 2019-01-03 2020-07-09 주식회사 레고켐 바이오사이언스 안전성이 향상된 피롤로벤조디아제핀 이량체 화합물 및 이의 용도
KR20200084802A (ko) 2019-01-03 2020-07-13 주식회사 레고켐 바이오사이언스 안전성이 향상된 피롤로벤조디아제핀 이량체 화합물 및 이의 용도
BR112021017303A2 (pt) 2019-03-06 2021-11-16 Legochem Biosciences Inc Conjugado de anticorpo ou um sal ou solvato farmaceuticamente aceitável deste, anticorpo que se liga com especificidade ao dlk1 ou um fragmento de ligação ao antígeno deste, composição farmacêutica para prevenção ou tratamento de doença proliferativa, câncer ou angiogênica, métodos para prevenção e para tratamento de doença proliferativa, câncer ou angiogênica, e, uso do conjugado
KR20210028544A (ko) * 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
WO2021137646A1 (ko) 2019-12-31 2021-07-08 주식회사 레고켐바이오사이언스 피롤로벤조디아제핀 유도체 및 이의 리간드-링커 접합체
WO2022211508A1 (ko) 2021-03-30 2022-10-06 주식회사 레고켐바이오사이언스 인간 cldn18.2에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
GB202203070D0 (en) * 2022-03-04 2022-04-20 Iksuda Therapeutics Ltd Anti-canag antibody conjugate
CN115429890B (zh) * 2022-08-04 2024-05-24 辽宁键凯科技有限公司 一种缀合物及用其制备的抗体药物偶联物
CN115772163B (zh) * 2022-12-09 2025-07-22 中国科学院成都生物研究所 吲哚糖苷类化合物及吡咯糖苷类化合物及合成方法与应用
EP4389152A1 (en) 2022-12-23 2024-06-26 Synaffix B.V. Conjugates of pbd prodrugs
CN120857932A (zh) * 2023-02-22 2025-10-28 坚毅科学股份有限公司 用于靶向肿瘤相关巨噬细胞的组合物和方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013523895A (ja) 2010-04-15 2013-06-17 スピロゲン ディベロップメンツ エスアーエールエル ピロロベンゾジアゼピン及びそれらのコンジュゲート
JP2016539915A (ja) 2013-10-11 2016-12-22 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン類およびその複合体

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112739A (en) 1988-08-02 1992-05-12 Polaroid Corporation Enzyme controlled release system
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
DE19512484A1 (de) 1995-04-04 1996-10-17 Bayer Ag Kohlenhydratmodifizierte Cytostatika
SI0795334T1 (sl) 1996-03-12 2006-06-30 Sanofi Aventis Deutschland Predzdravila za zdravljenje tumorjev in vnetnih bolezni
US6218519B1 (en) 1996-04-12 2001-04-17 Pro-Neuron, Inc. Compounds and methods for the selective treatment of cancer and bacterial infections
AU5159798A (en) 1996-11-05 1998-05-29 Bristol-Myers Squibb Company Branched peptide linkers
US6759509B1 (en) 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
AU758575C (en) 1998-04-30 2003-11-20 Maruha Corporation Compounds having glucuronic acid derivative and glucosamine derivative in structure thereof, method for producing the compounds, and uses of the compounds
GB0226593D0 (en) 2002-11-14 2002-12-24 Consultants Ltd Compounds
EP1581218A1 (en) 2002-12-05 2005-10-05 Schering AG Epothilone analogs for site specific delivery in the treatment of proliferative diseases
ES2456325T3 (es) 2003-11-06 2014-04-22 Seattle Genetics, Inc. Compuestos de monometilvalina capaces de conjugación con ligandos
EP1701955A1 (en) 2003-12-29 2006-09-20 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
WO2006009832A1 (en) 2004-06-18 2006-01-26 3M Innovative Properties Company Substituted imidazo ring systems and methods
EP1786469A2 (en) 2004-09-10 2007-05-23 Wyeth a Corporation of the State of Delaware Humanized anti-5t4 antibodies and anti-5t4 antibody / calicheamicin conjugates
WO2006091647A2 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
DK1912671T3 (da) 2005-07-18 2017-11-27 Seattle Genetics Inc Beta-glucuronid-linker-lægemiddelkonjugater
CN101287500A (zh) 2005-08-19 2008-10-15 恩多塞特公司 多药物配体缀合物
MX2009001293A (es) 2006-08-03 2009-02-11 Astrazeneca Ab Anticuerpos dirigidos a (v(6 y usos de los mismos.
WO2008034120A2 (en) 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Lysine-based polymeric linkers
SI2061814T1 (sl) 2006-10-27 2012-09-28 Genentech Inc Protitelesa in imunokonjugati in njihove uporabe
EP2096122B1 (en) 2006-11-10 2014-07-16 Livtech Inc. Anti-human dlk-1 antibody showing anti-tumor activity in vivo
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
EP2188297B1 (en) 2007-08-01 2012-02-01 Council of Scientific & Industrial Research Pyrrolo [2,1-c][1, 4] benzodiazepine-glycoside prodrugs useful as a selective anti tumor agent
AU2008312457B2 (en) 2007-10-19 2014-04-17 Genentech, Inc. Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates
ES2527521T3 (es) 2008-03-17 2015-01-26 Livtech Inc. Anticuerpos antihumanos frente a Dlk-1 que tienen actividad antitumoral
US9073913B2 (en) 2008-03-24 2015-07-07 4Sc Ag Substituted imidazoquinolines
GB0819097D0 (en) 2008-10-17 2008-11-26 Spirogen Ltd Pyrrolobenzodiazepines
CA2759733C (en) 2009-04-23 2019-09-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ror1 antibodies
WO2011066418A1 (en) 2009-11-25 2011-06-03 Academia Sinica The tumor-selective anti-cancer prodrug bqc-g
KR20110075542A (ko) 2009-12-28 2011-07-06 주식회사 효성 연료전지 시스템의 워터트랩 장치
ES2623057T3 (es) 2010-04-15 2017-07-10 Medimmune Limited Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas
FR2960153B1 (fr) 2010-05-20 2012-08-17 Centre Nat Rech Scient Nouveaux bras autoreactifs et prodrogues les comprenant
US9591882B2 (en) 2010-08-05 2017-03-14 Robert LaGrand Duffin Absorbent sleeve
EP2621954A1 (en) 2010-10-01 2013-08-07 Oxford Biotherapeutics Ltd. Anti-rori antibodies
GB201020995D0 (en) 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
KR20120107741A (ko) 2011-03-22 2012-10-04 한국생명공학연구원 패혈증 단백질 치료제의 효능 분석 및 스크리닝 방법
KR101438265B1 (ko) 2011-04-04 2014-09-05 한국생명공학연구원 Ｄｌｋ１ 특이적 인간 항체 및 이를 포함하는 약학적 조성물
WO2012138102A2 (ko) 2011-04-04 2012-10-11 한국생명공학연구원 Ｄｌｋ１ 특이적 인간 항체 및 이를 포함하는 약학적 조성물
WO2012148427A1 (en) 2011-04-29 2012-11-01 Hewlett-Packard Development Company, L.P. Systems and methods for in-memory processing of events
CA2835576C (en) 2011-05-08 2021-01-05 Legochem Biosciences, Inc. Protein-active agent conjugates and method for preparing the same
CA2850373C (en) 2011-10-14 2019-07-16 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
US9884123B2 (en) 2012-01-03 2018-02-06 Invictus Oncology Pvt. Ltd. Ligand-targeted molecules and methods thereof
EP2855482B1 (en) 2012-04-30 2017-03-01 MedImmune Limited Pyrrolobenzodiazepines
PT2906253T (pt) 2012-10-12 2018-11-05 Medimmune Ltd Conjugados de anticorpo anti-psma de pirrolobenzodiazepina
WO2014096368A1 (en) * 2012-12-21 2014-06-26 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
KR102066319B1 (ko) * 2013-03-13 2020-01-14 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨쥬게이트
WO2014143765A1 (en) 2013-03-15 2014-09-18 Abbvie Deutschland Gmbh & Co.Kg Anti-egfr antibody drug conjugate formulations
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
US20160256561A1 (en) 2013-10-11 2016-09-08 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
JP6747971B2 (ja) 2013-10-15 2020-08-26 シアトル ジェネティックス， インコーポレイテッド 改善されたリガンド−薬物コンジュゲート薬物動態のためのｐｅｇ化薬物−リンカー
EA201691075A1 (ru) 2013-11-26 2016-09-30 Новартис Аг Способы оксимной конъюгации с кетон-модифицированными полипептидами
IL290330B2 (en) 2013-12-19 2023-09-01 Seagen Inc Methylene carbamate binders for use with drug-targeting conjugates
EP2913064A1 (en) 2014-02-26 2015-09-02 celares GmbH Branched drug-linker conjugates for the coupling to biological targeting molecules
KR101628872B1 (ko) * 2014-05-28 2016-06-09 주식회사 레고켐 바이오사이언스 자가-희생 기를 포함하는 화합물
TWI805109B (zh) 2014-08-28 2023-06-11 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
AU2015315007C1 (en) 2014-09-11 2021-06-03 Seagen Inc. Targeted delivery of tertiary amine-containing drug substances
US10434412B2 (en) 2014-10-24 2019-10-08 Sony Interactive Entertainment Inc. Control apparatus, control method, program, and information storage medium
WO2016063595A1 (ja) 2014-10-24 2016-04-28 ソニー株式会社 画像処理装置、画像処理方法及びプログラム
EP3230283A1 (en) 2014-12-09 2017-10-18 AbbVie Inc. Bcl-xl inhibitory compounds and antibody drug conjugates including the same
KR20160080832A (ko) 2014-12-29 2016-07-08 주식회사 레고켐 바이오사이언스 리피바디 유도체-약물 복합체, 그 제조방법 및 용도
WO2016115345A1 (en) 2015-01-14 2016-07-21 The Brigham And Women's Hospital, Treatment of cancer with anti-lap monoclonal antibodies
KR20170128234A (ko) 2015-01-16 2017-11-22 주노 쎄러퓨티크스 인코퍼레이티드 Ror1에 특이적인 항체 및 키메라 항원 수용체
KR102587808B1 (ko) 2015-01-30 2023-10-10 서트로 바이오파마, 인크. 접합 및 요법을 위한 헤미아스텔린 유도체
WO2016142768A1 (en) 2015-03-10 2016-09-15 Eureka Therapeutics, Inc. Ror2 antibody
HK1253507A1 (zh) 2015-05-18 2019-06-21 Eureka Therapeutics, Inc. 抗 ror1 抗體
WO2017051254A1 (en) 2015-09-25 2017-03-30 Legochem Biosciences, Inc. Compositions and methods related to anti-egfr antibody drug conjugates
WO2017051249A1 (en) 2015-09-25 2017-03-30 Legochem Biosciences, Inc. Compositions and methods related to anti-cd19 antibody drug conjugates
JP7017015B2 (ja) 2015-10-13 2022-02-08 エウレカ セラピューティクス インコーポレイテッド ヒトｃｄ１９に特異的な抗体剤及びその使用
CA3006249A1 (en) 2015-11-25 2017-06-01 Legochem Biosciences, Inc. Antibody-drug conjugates comprising branched linkers and methods related thereto
WO2017089894A1 (en) 2015-11-25 2017-06-01 Legochem Biosciences, Inc. Conjugates comprising peptide groups and methods related thereto
HRP20240795T1 (hr) 2015-11-25 2024-09-13 Ligachem Biosciences Inc. Konjugati koji se sastoje od samozapaljujućih skupina i postupci povezani s njima
RU2651776C2 (ru) 2015-12-01 2018-04-23 Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") Биспецифические антитела против cd3*cd19
CN108848669B (zh) 2016-01-20 2022-06-07 斯克利普斯研究所 Ror1抗体组合物和相关方法
US10822311B2 (en) 2016-03-14 2020-11-03 Afferent Pharmaceuticals, Inc. Pyrimidines and variants thereof, and uses therefor
ES2921855T3 (es) 2016-04-07 2022-09-01 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas útiles como moduladores de proteínas
CA3020873A1 (en) 2016-04-15 2017-10-19 Dynavax Technologies Corporation Intratumoral administration of particles containing a toll-like receptor 9 agonist and a tumor antigen for treating cancer
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
US20180142018A1 (en) 2016-11-04 2018-05-24 Novimmune Sa Anti-cd19 antibodies and methods of use thereof
CA3044274A1 (en) 2016-11-21 2018-05-24 Obi Pharma, Inc. Conjugated biological molecules, pharmaceutical compositions and methods
US20200338210A1 (en) 2016-12-22 2020-10-29 Ardeagen Corporation Anti-ror1 antibody and conjugates thereof
JP6704532B1 (ja) 2017-02-08 2020-06-03 アーデーセー セラピューティクス ソシエテ アノニム ピロロベンゾジアゼピン抗体複合体
WO2018182341A1 (ko) 2017-03-29 2018-10-04 주식회사 레고켐 바이오사이언스 피롤로벤조디아제핀 이량체 전구체 및 이의 리간드-링커 접합체 화합물
IL269535B2 (en) 2017-03-29 2024-11-01 Ligachem Biosciences Inc Pyrrolobenzodiazepine dimer prodrug and ligand-linker conjugate compound of the same
AR113224A1 (es) 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
WO2018237335A1 (en) 2017-06-23 2018-12-27 VelosBio Inc. IMMUNOCONJUGUATED ROR1 ANTIBODIES
KR20190018400A (ko) 2017-08-14 2019-02-22 주식회사 레고켐 바이오사이언스 EGFRvIII에 대한 항체를 포함하는 항체 약물 접합체
EP3683236A4 (en) 2017-09-08 2021-10-13 Y-Biologics Inc. ANTIBODIES DIRECTED AGAINST HUMAN DLK1 AND ASSOCIATED USE
WO2019051489A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
US11638760B2 (en) 2017-11-27 2023-05-02 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
EP4600271A3 (en) 2017-12-15 2025-11-12 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Bioactive molecule conjugate, preparation method and use thereof
EP3790591A4 (en) 2018-05-09 2022-05-11 LegoChem Biosciences, Inc. Compositions and methods related to anti-cd19 antibody drug conjugates
WO2019225777A1 (ko) 2018-05-23 2019-11-28 에이비엘바이오 주식회사 항-ror1 항체 및 그 용도
WO2019227007A1 (en) 2018-05-25 2019-11-28 Incyte Corporation Tricyclic heterocyclic compounds as sting activators
WO2019243825A1 (en) 2018-06-21 2019-12-26 Curadev Pharma Limited Small molecule modulators of human sting, conjugates and therapeutic applications
CN110903395A (zh) 2018-09-14 2020-03-24 四川科伦博泰生物医药股份有限公司 抗体、偶联物及其制备方法和用途
EP3873938A1 (en) 2018-10-31 2021-09-08 Novartis AG Dc-sign antibody conjugates comprising sting agonists
KR20200084802A (ko) 2019-01-03 2020-07-13 주식회사 레고켐 바이오사이언스 안전성이 향상된 피롤로벤조디아제핀 이량체 화합물 및 이의 용도
BR112021017303A2 (pt) 2019-03-06 2021-11-16 Legochem Biosciences Inc Conjugado de anticorpo ou um sal ou solvato farmaceuticamente aceitável deste, anticorpo que se liga com especificidade ao dlk1 ou um fragmento de ligação ao antígeno deste, composição farmacêutica para prevenção ou tratamento de doença proliferativa, câncer ou angiogênica, métodos para prevenção e para tratamento de doença proliferativa, câncer ou angiogênica, e, uso do conjugado
EP3983078B1 (en) 2019-06-12 2023-11-15 Ryvu Therapeutics S.A. Next-generation modulators of stimulator of interferon genes (sting)
BR112022001125A2 (pt) 2019-07-22 2022-03-15 Lupin Ltd Compostos macrocíclicos como agonistas de sting, seus métodos e seus usos
TW202120500A (zh) 2019-08-02 2021-06-01 美商梅爾莎納醫療公司 干擾素基因刺激蛋白（ｓｔｉｎｇ）激動劑化合物及用途
KR20210028544A (ko) 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
WO2021046426A1 (en) 2019-09-06 2021-03-11 Sperovie Biosciences, Inc. Cyclic dinucleotide sting agonists tethered to a pd-1 or ctla-4 antibodies
US11184191B1 (en) 2019-09-12 2021-11-23 Trend Micro Incorporated Inspection of network traffic on accelerated platforms
EP4228701A1 (en) 2020-10-19 2023-08-23 Vaccitech North America, Inc. Star polymer drug conjugates
MX2023008000A (es) 2021-01-04 2023-07-13 Mersana Therapeutics Inc Conjugados de anticuerpo dirigido a b7-h4 y farmaco, y metodos de uso de los mismos.
CA3207893A1 (en) 2021-01-15 2022-07-21 Seagen Inc. Immunomodulatory antibody-drug conjugates
WO2022177307A1 (ko) 2021-02-17 2022-08-25 한국화학연구원 벤즈이미다졸 유도체를 유효 성분으로 포함하는 인터페론 유전자 자극제 조성물
WO2022211508A1 (ko) 2021-03-30 2022-10-06 주식회사 레고켐바이오사이언스 인간 cldn18.2에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
US20250090681A1 (en) 2021-06-03 2025-03-20 Orum Therapeutics, Inc. Neodegrader conjugates
CN119451956A (zh) 2022-04-29 2025-02-14 瑞嘉化学生物科学股份有限公司 作为tlr7/8调节剂的咪唑并[4,5-c]吡啶衍生化合物
AU2023378494A1 (en) 2022-11-08 2025-06-12 Ligachem Biosciences Inc. Sting agonists
CN120835796A (zh) 2023-03-10 2025-10-24 瑞嘉化学生物科学股份有限公司 包括抗人类l1cam抗体的抗体-药物偶联物和其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013523895A (ja) 2010-04-15 2013-06-17 スピロゲン ディベロップメンツ エスアーエールエル ピロロベンゾジアゼピン及びそれらのコンジュゲート
JP2016539915A (ja) 2013-10-11 2016-12-22 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン類およびその複合体

Also Published As

Publication number Publication date
US20230270868A1 (en) 2023-08-31
IL269535B1 (en) 2024-07-01
KR101938800B1 (ko) 2019-04-10
CN109790171A (zh) 2019-05-21
NZ757701A (en) 2024-07-05
KR20180110649A (ko) 2018-10-10
AU2018246806A1 (en) 2019-10-17
EP3604311A1 (en) 2020-02-05
US12398124B2 (en) 2025-08-26
KR20220010048A (ko) 2022-01-25
US20220218830A1 (en) 2022-07-14
IL269535B2 (en) 2024-11-01
CA3058360A1 (en) 2018-10-04
BR112019020136A2 (pt) 2020-04-22
IL269535A (enExample) 2020-02-27
AU2018246806B2 (en) 2022-05-12
KR20210058795A (ko) 2021-05-24
KR102489250B1 (ko) 2023-01-17
CN109790171B (zh) 2022-07-26
KR20180110645A (ko) 2018-10-10
EP3604311A4 (en) 2021-01-13
JP2023113699A (ja) 2023-08-16
JP2020512270A (ja) 2020-04-23
MX2019011655A (es) 2019-12-19
US11654197B2 (en) 2023-05-23

Similar Documents

Publication Publication Date Title
JP7664680B2 (ja) ピロロベンゾジアゼピン二量体前駆体及びそのリガンド－リンカーコンジュゲート化合物
KR101671360B1 (ko) 표적화된 피롤로벤조디아제핀 접합체
KR102591073B1 (ko) 안전성이 향상된 피롤로벤조디아제핀 이량체 화합물 및 이의 용도
WO2022253033A1 (zh) 一类化学偶联连接子及其用途
EP3907226A2 (en) Pyrrolobenzodiazepine dimer compound with improved safety and use thereof
US20230310640A1 (en) Pyrrolobenzodiazepine derivative and ligand-linker conjugate thereof
TWI712605B (zh) 含有ｃｔｉ藥效基團之雙功能性細胞毒性劑
HK40008493B (en) Pyrrolobenzodiazepine dimer precursor and ligand-linker conjugate compound thereof
HK40008493A (en) Pyrrolobenzodiazepine dimer precursor and ligand-linker conjugate compound thereof
CN107660208B (zh) 包含cti药效团的双功能细胞毒性剂
BR112019020136B1 (pt) Conjugado de profármaco de dímero de pirrolobenzodiazepina, composição farmacêutica compreendendo o mesmo e uso terapêutico do mesmo
TW202540181A (zh) 抗體－光敏感性物質複合體
CN118541378A (zh) 新型澳瑞他汀类似物及其免疫偶联物
WO2025175039A1 (en) Duocarmycin analogs and applications thereof
HK1232526A1 (en) Antibody drug conjugate, intermediate, preparation method, pharmaceutical composition and application thereof
HK1245252B (zh) 包含cti药效团的双功能细胞毒性剂
HK1232526B (zh) 抗体药物偶联物、中间体、制备方法、药物组合物及应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190903

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20190903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210329

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210329

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220621

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221017

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230517

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230526

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241226

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250408

R150 Certificate of patent or registration of utility model

Ref document number: 7664680

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150